C. Eberlein

发表

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

S. Barry, J. Kendrew, V. Bedian, 2012, Molecular Cancer Therapeutics.

Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model

M. Shibuya, S. Barry, S. Wedge, 2010, Angiogenesis.

Development of a bispecific Antibody–Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia

O. Schon, J. Slupsky, C. Eberlein, 2022, bioRxiv.

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

M. Garnett, S. Barry, B. Davies, 2022, Oncogene.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

A. Biankin, S. Barry, D. Chang, 2016, Cancer cell.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

William Pao, Peter Ballard, Hailing Jin, 2014, Cancer discovery.

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

M. Braddock, J. Curwen, Jianyang Wang, 2015, Pharmacology research & perspectives.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Matthew Grist, M Raymond V Finlay, Richard A Ward, 2013, Journal of medicinal chemistry.

E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling

S. Barry, H. Weir, S. Ross, 2014, Oncogene.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

S. Barry, Paul D. Smith, J. Kendrew, 2016, Cell metabolism.

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

S. Barry, O. Delpuech, Á. Avivar-Valderas, 2018, Molecular Cancer Therapeutics.

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

E. Hennessy, C. Chuaqui, J. Debreczeni, 2016, ACS medicinal chemistry letters.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

S. Barry, S. Wedge, J. Kendrew, 2011, Molecular Cancer Therapeutics.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

S. Barry, J. Kendrew, V. Bedian, 2013, Oncogene.

CXCR 2 Inhibition Profoun dly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Graphical Abstract Highlights

A. Biankin, S. Barry, D. Chang, 2016 .

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

S. Ashton, Matthew J. Martin, D. Cross, 2016, Oncotarget.

Mixed micelles of lipoic acid‐chitosan‐poly(ethylene glycol) and distearoylphosphatidylethanolamine‐poly(ethylene glycol) for tumor delivery

K. Taylor, K. Al‐Jamal, B. Forbes, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

S. Barry, C. Rooney, J. Urosevic, 2023, NPJ breast cancer.

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole

S. Barry, R. Sommavilla, C. Eberlein, 2023, Clinical pharmacology in drug development.

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

W. Pao, S. Ashton, D. Cross, 2013 .

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

W. Pao, M. Ranson, Hailing Jin, 2014, Cancer discovery.

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

S. Barry, J. Kendrew, V. Bedian, 2012, Molecular Cancer Therapeutics.